Literature DB >> 23627786

Can MDMA play a role in the treatment of substance abuse?

Lisa Jerome1, Shira Schuster, B Berra Yazar-Klosinski.   

Abstract

A wider array of treatments are needed for people with substance abuse disorders. Some psychedelic compounds have been assessed as potential substance abuse treatments with promising results. MDMA may also help treat substance abuse based on shared features with psychedelic compounds and recent reports indicating that MDMAassisted psychotherapy can reduce symptoms of PTSD. Narrative reports and data from early investigations found that some people reduced or eliminated their substance use after receiving MDMA, especially in a therapeutic setting. MDMA is a potent monoamine releaser with sympathomimetic effects that may indirectly activate 5-HT2A receptors. It increases interpersonal closeness and prosocial feelings, potentially through oxytocin release. Findings suggest that ecstasy, material represented as containing MDMA, is associated with deleterious long-term effects after heavy lifetime use, including fewer serotonin transporter sites and impaired verbal memory. Animal and human studies demonstrate moderate abuse liability for MDMA, and this effect may be of most concern to those treating substance abuse disorders. However, subjects who received MDMA-assisted psychotherapy in two recent clinical studies were not motivated to seek out ecstasy, and tested negative in random drug tests during follow-up in one study. MDMA could either directly treat neuropharmacological abnormalities associated with addiction, or it could indirectly assist with the therapeutic process or reduce symptoms of comorbid psychiatric conditions, providing a greater opportunity to address problematic substance use. Studies directly testing MDMA-assisted psychotherapy in people with active substance abuse disorder may be warranted.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23627786     DOI: 10.2174/18744737112059990005

Source DB:  PubMed          Journal:  Curr Drug Abuse Rev        ISSN: 1874-4737


  8 in total

Review 1.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

2.  First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants.

Authors:  Ben Sessa; Chloe Sakal; Steve O'Brien; David Nutt
Journal:  BMJ Case Rep       Date:  2019-07-15

Review 3.  Progress and promise for the MDMA drug development program.

Authors:  Allison A Feduccia; Julie Holland; Michael C Mithoefer
Journal:  Psychopharmacology (Berl)       Date:  2017-11-20       Impact factor: 4.530

Review 4.  (±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA.

Authors:  Elizabeth G Pitts; Daniel W Curry; Karly N Hampshire; Matthew B Young; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-12-16       Impact factor: 4.530

5.  Regular MDMA use is associated with decreased risk of drug injection among street-involved youth who use illicit drugs.

Authors:  Andrew Gaddis; Stephanie Lake; Kenneth Tupper; Ekaterina Nosova; Katrina Blommaert; Evan Wood; Kora DeBeck
Journal:  Drug Alcohol Depend       Date:  2018-09-12       Impact factor: 4.492

Review 6.  Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy.

Authors:  Hans Emanuel Oeri
Journal:  J Psychopharmacol       Date:  2020-09-10       Impact factor: 4.153

Review 7.  Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist's Perspective.

Authors:  Ben Sessa
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

Review 8.  3,4-methylenedioxymethamphetamine (MDMA): current perspectives.

Authors:  Jerrold S Meyer
Journal:  Subst Abuse Rehabil       Date:  2013-11-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.